Figure 1.
Representation of plaque progression with drug molecular actions. BBR: BerBeRine; CoQ10: Coenzyme Q110; DHA: DocosaHexaenoic Acid; DPP4is: DiPeptidyl Peptidase 4 inhibitors; EGCG: EpiGalloCatechin-3-Gallate; GIP: Glucose-dependent Insulinotropic Polypeptide; GLP-1 Ras; Glucagon Like Peptide-1 Receptor agonists; PCSK9is: Proprotein Convertase Subtilisin/Kexin 9 inhibitors; TSG: 2,3,4,5′-TetrahydroxyStilbene-2-o-β-d-Glucoside.